Study #2018-0224
A Phase 1/2 Study of Gemcitabine and Docetaxel in Combination with Hydroxychloroquine (Autophagy Inhibitor) in Patients with Recurrent Osteosarcoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Docetaxel, Gemcitabine, Hydroxychloroquine
Description
This phase I/II trial studies the side effects and best dose of hydroxychloroquine and how well it works when given together with gemcitabine and docetaxel in treating participants with osteosarcoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as gemcitabine, docetaxel, and hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Recurrent Osteosarcoma, Refractory Osteosarcoma
Study phase:
Physician name:
John Livingston
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.